IN8BIO, Inc.

INAB

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001740279

SEC filings (opens in a new tab)

No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding IN8BIO, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022 All holders in Q1 2022

13F holders of INAB: Q1 2022 compared with Q2 2022
Measure	Q1 2022	Q2 2022	Change
Holders	14	15	+1
Shares	2.05M	2.36M	+308.0K (+15.0%)
Value	$7.02M	$5.50M	−$1.51M (−21.6%)

New holders (2)

Institutions that held IN8BIO, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to INAB in Q2 2022
Institution	Shares	Value	% of portfolio
Stonegate Investment Group, LLC	266,500	$602.0K	0.03%
Two Sigma Securities, LLC	29,858	$67.0K	0.01%

Sold out (1)

Institutions that held IN8BIO, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of INAB in Q2 2022
Institution	Shares, Q1 2022	Value, Q1 2022
HighTower Advisors, LLC	14,164	$47.0K